We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Brain Cancer

Journal Scan / Research · November 22, 2021

Outcomes With Pembrolizumab Plus Platinum-Based Chemotherapy for Patients With NSCLC and Stable Brain Metastases: Pooled Analysis of KEYNOTE-021, -189, and -407

Journal of Thoracic Oncology

 

Additional Info

Disclosure statements are available on the authors' profiles:

Journal of Thoracic Oncology
Outcomes With Pembrolizumab Plus Platinum-Based Chemotherapy for Patients With NSCLC and Stable Brain Metastases: Pooled Analysis of KEYNOTE-021, -189, and -407
J Thorac Oncol 2021 Nov 01;16(11)1883-1892, SF Powell, D Rodríguez-Abreu, CJ Langer, A Tafreshi, L Paz-Ares, HG Kopp, J Rodríguez-Cid, DM Kowalski, Y Cheng, T Kurata, MM Awad, J Lin, B Zhao, MC Pietanza, B Piperdi, MC Garassino

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading